Claus Braestrup - Evotec AG Insider

EVOTF -- USA Stock  

USD 17.48  0.00  0.00%

Member of the Supervisory Board
Dr. Claus T. Braestrup, M.D., was Member of the Supervisory Board of Evotec AG since June 12, 2013. He is Member of the Audit Committee at the Company. During his career, he gained experience from publicly traded international pharmaceutical companies as well as scientific and drug discovery qualifications. From 2003 to 2008, he served as President and CEO at H. Lundbeck AS, where he was head of research and development from 1998 to 2003. Previously, he served as head of preclinical drug research at Schering AG from 1994 to 1998, at Novo Nordisk AS as president of the Diabetes Care Division, President of its CNS Division and Vice President of pharmaceutical research and at Ferrosan AS as scientist in drug discovery from 1978 to 1984. He serves as Chairman of the Board of Saniona AB and as Member of the Board of Bavarian Nordic AS, Kastan ApS and Evolva SA. He holds a Masters degree in Chemical Engineering and is MS in Biochemistry. He is Doctor of Medical Science and former Adjunct Professor in Neuroscience at the University of Copenhagen.
Age: 72  Executive Since 2013      
49 40 5 60 81 0  http://www.evotec.com

Management Efficiency

The company has return on total asset (ROA) of 4.3 % which means that it generated profit of $4.3 on every $100 spent on asset. This is normal as compared to the sector avarege. Similarly, it shows return on equity (ROE) of 6.24 % meaning that it generated $6.24 on every $100 dollars invested by stockholders.
The company has accumulated 212.96 M in total debt with debt to equity ratio (D/E) of 53.8 indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Evotec AG has Current Ratio of 0.72 indicating that it has a negative working capital and may not be able to pay financial obligations in time and when they become due.

Similar Executives

Showing few of many executives

EXECUTIVE Since

Minzheng DaiChina Steel Corporation
2014
ChunLung WuChina Steel Corporation
2016
ShinMin LeeChina Steel Corporation
2016
Yuanquan HongChina Steel Corporation
2014
Lin ChungYiChina Steel Corporation
2014
HsinChin KuoChina Steel Corporation
2016
MingHsien WuChina Steel Corporation
2016
ChingChung ChengChina Steel Corporation
2015
ChungYi LinChina Steel Corporation
2014
YuanChuan HorngChina Steel Corporation
2014
SongJau TsaiChina Steel Corporation
2018
TsanYing HoChina Steel Corporation
2015
ChungTe ChenChina Steel Corporation
2017
Maobin WangChina Steel Corporation
2014
Hsiung LiChina Steel Corporation
2011
Zongde ChenChina Steel Corporation
2017
Xiong LiChina Steel Corporation
2011
HsiuChang LiangChina Steel Corporation
2015
Xiqin WangChina Steel Corporation
2012
YiLang LinChina Steel Corporation
N/A
Chi LiaoChina Jinmao Holdings Group Lim
2007

Entity Summary

Evotec AG provides drug discovery and development solutions to pharmaceutical and biotechnology companies, academic institutions, foundations, and not-for-profit organizations worldwide. Evotec AG was founded in 1993 and is headquartered in Hamburg, Germany. Evotec AG operates under Drug Manufacturers - Specialty Generic classification in USA and traded on OTC Market. It employs 2178 people.Evotec AG (EVOTF) is traded on OTC Market in USA. It is located in Manfred Eigen Campus and employs 2,178 people.

Evotec AG Leadership Team

Werner Lanthaler, CEO
Claus Braestrup, Executive
Michael Shalmi, Executive, MBA
Mario Polywka, COO, Ph.D
Mary Tanner, Executive
Roland Oetker, Chairman
Andreas Pinkwart, Executive
Paul Herrling, Executive, Ph.D
Colin Bond, CFO, MBA
Cord Dohrmann, Executive
Iris LoewFriedrich, Executive, Ph.D
Bernd Hirsch, Executive
Enno Spillner, CFO
Elaine Sullivan, Executive
Wolfgang Plischke, Chairman, Ph.D

Stock Performance Indicators

Current Sentiment - EVOTF

Evotec AG Investor Sentiment
Macroaxis portfolio users are insensible in their opinion about investing in Evotec AG. What is your opinion about investing in Evotec AG? Are you bullish or bearish?
Bullish
Bearish
50% Bullish
50% Bearish
Skip

Pair Correlation

Equities Pair Trading Analysis
Correlation analysis and pair trading evaluation for Evotec AG and China Steel. Pair trading can be used as a hedging technique within a particular sector or industry or even over random equities to generate better risk-adjusted return
Run Pair Correlation  
Additionally see Investing Opportunities. Please also try Money Managers module to screen money managers from public funds and etfs managed around the world.